Analysts rate Moderna Inc(MRNA:NSD) with an Under-perform rating and a $150 target

by: Gillian Lawrence
Moderna Inc

Analysts rate Moderna Inc with a consensus Under-perform rating and a 12-month average target price of $150.93 per share.

Based on the Moderna Inc stock forecasts from 7 analysts, the average analyst target price for Moderna Inc is USD 150.93 over the next 12 months. Moderna Inc’s average analyst rating is Under-perform. Stock Target Advisor’s own stock analysis of Moderna Inc is Bullish , which is based on 10 positive signals and 4 negative signals. At the last closing, Moderna Inc’s stock price was USD 171.18Moderna Inc’s stock price has changed by -8.38% over the past week, +7.04% over the past month and -56.08% over the last year.

News:

In April, Moderna said that it would construct a factory in the Montreal region to produce around 30 million doses of vaccine annually, with the option to increase that number to 100 million if necessary, which would create approximately 200 to 300 jobs.

According to Moderna, it has agreed to buy land in the biotechnology park of a Montreal suburb to house its biomanufacturing factory.  The Massachusetts-based corporation claims that the location is suitable since it is home to a campus of the Institut National de la Recherche Scientifique, a prominent Quebec research institute (INRS).

The new Moderna mRNA vaccine plant in Laval, Quebec, is scheduled to begin building later this year, with production projected to start by the end of 2024.  It will be the pharmaceutical giant’s first production site outside of the US, with an estimated $180 million construction cost.

In addition to COVID-19 vaccines, the facility is anticipated to develop vaccines for influenza and respiratory syncytial virus, or RSV, as well as other respiratory viruses.

What we like:

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What we don’t like:

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Disclaimer

Stock Target Advisor is not a broker/dealer, investment advisor, or platform for making stock buying or selling decisions. Our goal is to democratize and simplify financial information through automated analysis, aggregation of stock information, and education to help investors with their research. No content on our site, blogs or newsletters constitutes – or should be understood as constituting – a recommendation to enter into any securities transactions or to engage in any of the investment strategies presented in our site content. We also cannot guarantee the accuracy of any information presented on our site and in our analysis.

Leave a Reply

Your email address will not be published.